New River Pharmaceuticals — Technical Presentation (June 2006)
19 slides from New River Pharmaceuticals's technical presentation, Jun 19, 2006

Slide 1: Pharmacokinetics of Oral Lisdexamfetamine Dimesylate Versus d-Amphetamine Sulfate
Pharmacokinetics of Oral Lisdexamfetamine Dimesylate (LDX; NRP 104) Versus d- Amphetamine Sulfate in Healthy Adults With a History of Stimulant Abuse (NRP104.A01) Donald Jasinski The Johns Hopkins University, Baltimore, MD Suma Krishnan New River Pharmaceuticals, Blacksburg, VA

Slide 2: LDX (lisdexamfetamine dimesylate): d-amphetamine bonded to l-lysine
d-amphetamine covalently bonded to l-lysine Pharmacologically inactive until cleaved via rate-limiting hydrolysis Resistant to manipulation and difficult to extract d-amphetamine LDX (lisdexamfetamine dimesylate)

Slide 3: Protocol Objectives
To determine safety and tolerability of single oral dose of lisdexamfetamine dimesylate (LDX) in 12 healthy adults with histories of stimulant abuse To compare PK profile of LDX with d- amphetamine and placebo To determine safe and tolerable dosing for further study Protocol Objectives

Slide 4: Design and Methodology
Partially randomized, single-blind, dose-escalation study; Subjects on inpatient unit at least 14 days Subjects met DSM-IV criteria for stimulant abuse; Screening for medical and psychiatric histories; naloxone challenge included Design and Methodology

Slide 5: Design and Methodology: Dosing Cohorts
Placebo LDX 30 mg, 50 mg, 70 mg, 100 mg d- amphetamine sulfate 40 mg Cohort = 4 Placebo LDX 50 mg, 70 mg, 100 mg, 130 mg d- amphetamine sulfate 40 mg Cohort = 4 Placebo LDX 70 mg, 100 mg, 130 mg, 150 mg d- amphetamine sulfate 40 mg Cohort = 4 Design and Methodology Minimum dosing interval: 48 h d-am

Slide 6: Patient Disposition
subjects were given at least 1 dose subjects completed the study subject was discontinued due to “reactive hypertension” after 2nd dose of d-amphetamine sulfate 40 mg Patient Disposition

Slide 7: d-amphetamine sulfate and LDX equal molar amounts of d-amphetamine base
d-amphetamine sulfate 40 mg and lisdexamfetamine dimesylate contain equal molar amounts of d-amphetamine base

Slide 8: Cohort plasma concentration charts
Cohort Cohort Cohort and Cohort 2

Slide 9: Plasma concentration over hours by dose
Hours - Placebo - 7OmgLDX -« 100 mgLDX -=- 130 mg LDX | 150mgLDX -* 40 mg d-amp

Slide 10: Pharmacokinetics by Cohort
LDX 100 mg d-amphetamine sulfate 40 mg Cohort T max d -amp (hours) C max d -amp (ng/mL) T max d -amp (hours) C max d -amp (ng/mL) 3.78 81.9 2.74 109.0 4.25 85.0 2.75 87.5 3.98 104.0 1.88 111.0 Pharmacokinetics by Cohort

Slide 11: Results
Results Dose appeared to attenuate between 130 to 150 mg of lisdexamfetamine Doses to 150 mg lisdexamfetamine safe and tolerable for further study Prolonged absorption phase as result of rate limiting hydrolysis

Slide 12: Double-Blind, Randomized, Placebo and Active-Controlled, Six-Period Crossover Study (NRP104.A03)
A Double-Blind, Randomized, Placebo and Active-Controlled, Six-Period Crossover Study to Evaluate the Likeability, Safety, and Abuse Liability of NRP 104 in Healthy Adult Volunteers with Histories of Stimulant Abuse (NRP104.A03)

Slide 13: Design and Methods
Design and Methods male and 6 female stimulant abusers Six 6X6 balanced Latin squares for crossover design Primary variable is maximum score on VAS scale to item “ How much do you like the drug effects you are feeling now?”

Slide 14: Drug and doses given orally
Drug and doses given orally Placebo mg d-amphetamine (Schedule II) mg diethylpropion (Schedule IV) Pro-drug Subjective and behavioral effects comparable to d-amphetamine 40 mg lisdexamfetamine mg (base = d-amp 20 mg) 100mg (base = d-amp 40 mg) mg (base = d-amp 60 mg)

Slide 15: Primary Endpoint: Peak Liking Score
Dependent Variable: Do you like the drug effect you are feeling now? Drug (I) Drug (J) Mean Difference (I – J) Std. Error Significance 95% Conf. Interval ( Lower Bound) d-amphetamine 40mg Placebo 4.53* 1.148 < 0.001 1.94 diethylpropion 200mg Placebo 4.03* 1.148 0.001 1.44 LDX 100mg Placebo 2.14 1.14

Slide 16: Primary Endpoint: Peak Liking Score (LDX doses)
Dependent Variable: Do you like the drug effect you are feeling now? Drug (I) Drug (J) Mean Difference (I – J) Std. Error Significance 95% Conf. Interval ( Lower Bound) LDX 50mg Placebo 1.97 1.148 0.148 -0.61 LDX 100mg Placebo 2.14 1.148 0.113 -0.45 LDX 150mg Placebo 6.06* 1.148 0.001 3.47 Based on

Slide 17: Peak Liking Scores
d-amphetamine and diethylpropion 1.5 to 2 hours NRP104 to 4 hours Peak Liking Scores

Slide 18: Top Line Results
Top Line Results LDX attenuates onset and intensity of liking effects Liking effects of LDX 50 and 100mg not significantly different than placebo Liking effects of LDX 150 mg greater than placebo but similar to d-amphetamine and diethylpropion however mean peak effect delayed

Slide 19: Top Line Results
Top Line Results Rate limited hydrolysis of LDX in humans Pro-drug attenuates onset and intensity of amphetamine like effects Attenuated Liking Scale scores Less reinforcing than equivalent d-amphetamine or diethylpropion Contribute to lesser abuse potential
Source: SEC EDGAR · 8-K filed Jun 19, 2006
More decks from New River Pharmaceuticals Inc
Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference 20078 slides · Feb 6, 2007
Bear Stearns 19th Annual Investor Conference 200614 slides · Sep 12, 2006
Technical Presentation (June 2006)46 slides · Jun 26, 2006
Technical Presentation (June 2006)8 slides · Jun 20, 2006
Merrill Lynch Healthcare Conference 200610 slides · Feb 7, 2006
First Albany Capital Annual Growth Conference 200521 slides · Dec 7, 2005